

CORRIGENDUM

Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan

Shin-ichiro Miura, Atsutoshi Okabe, Yoshino Matsuo, Sadashiva S Karnik and Keiji Saku

Hypertension Research (2013) **36**, 476; doi:10.1038/hr.2013.16

Correction to: *Hypertension Research* (2013) **36**, 134–139; doi:10.1038/hr.2012.147; published online 4 October 2012

After the publication of this article, the authors noticed an error in Figure 2. The asterisk (*) was missing from the bar labeled 'Azilsartan' in the WT receptor group. The correct figure is shown below.

The authors would like to apologise for this error.




Figure 2 Percent of maximum IP production with or without $1\mu\text{M}$ of the ARBs or $0.1\mu\text{M}$ [Sar¹]Ang II in COS1 cells transiently expressing the WT, N111G, N111G/K199Q or N111G/Q257A AT₁ receptor. [Sar¹]Ang II or ARB was added to the medium for 10 min. Percentage (%) maximum IP production indicates [Sar¹]Ang II-induced IP production (1920 c.p.m.) in WT AT₁ receptor-transfected cells (100%) after adjusting for basal IP production (130 c.p.m.) without treatment in mock-treated cells (0%). * $P < 0.05$ vs. no treatment. # $P < 0.05$ vs. candesartan.